37th week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110223108 | GLUCAGON-LIKE PEPTIDE-2 AND ITS THERAPEUTIC USE - Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described. | 2011-09-15 |
20110223109 | DIAGNOSTIC SUBSTANCE FOR USE IN A METHOD FOR DETERMINING THE AGGRESSIVENESS OF A PROSTATE TUMOR AND DIAGNOSTIC METHOD - In order to determine the aggressiveness of a prostate tumor, a diagnostic substance is administered to a patient that includes a biomarker provided with a first label that is detectable with a detection device and that specifically binds to a VEGF molecule, and that contains a biomarker that binds specifically to a target molecule that occurs uniformly in the endothelium of blood vessels of healthy tissue and the blood vessels of a prostate tumor, and that is provided with a second label that is detectable with the detection device independently of the first label. | 2011-09-15 |
20110223110 | STABLE INDIUM-CONTAINING SEMICONDUCTOR NANOCRYSTALS - Nanocrystals having an indium-based core and methods for making them and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide higher quantum yields than known nanocrystals of similar composition, and they provide special advantages for certain applications because of their small size. | 2011-09-15 |
20110223111 | CALCIUM CARBONATE MICROSTRUCTURES USEFUL IN ENCAPSULATION APPLICATIONS AND A PROCESS FOR THE PREPARATION THEREOF - A facile method to synthesize stable calcium carbonate microstructures is demonstrated which allows in situ encapsulation of sensitive molecules like drugs. The methodology involves a macromolecular assembly of anionic polypeptide with cationic peptide oligomer to concurrently template and hold to stabilize the mineralized structure. The heterogeneously distributed mixture of anionic and cationic residues in the macromolecular assembly, similar to that is found in natural systems assists in recognizing and coassembling Ca | 2011-09-15 |
20110223112 | UNSATURATED POLYESTER COATED MAGNETIC ULTRA-FINE PARTICLES FOR BIOLOGICAL APPLICATIONS - Unsaturated polyesters e.g. poly (ethylene glycol fumarate) (PEGF) were developed as new coating materials for iron oxide nanoparticles. Different strategies were adopted in their synthesis to provide different characteristics including solubility, molecular weight and structure also degrees of unsaturation. After synthesis of the nanoparticles; the material was applied as a coating on them. These materials were applicable without further processing, however, coatings were cured via thermal, redox or photo initiated crosslinking on the nanoparticles to provide rigid shells on the surface of nanoparticles. | 2011-09-15 |
20110223113 | PROPELLANT FOR DOSING AEROSOLS COMPRISING PACKAGINGS - A pharmaceutical product includes a dosing aerosol containing a propellant, an effective quantity of adsorbent, a pharmaceutically active substance, substance formulation or substance mixture, and a packaging enclosing the adsorbent. A dosing aerosol is disclosed with the pharmaceutically active substance, substance formulation or substance mixture. | 2011-09-15 |
20110223114 | ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition. It particularly relates to an antimicrobial composition for cleansing or personal care. It is an object of the present invention to provide antimicrobial compositions that have relatively fast antimicrobial action. Present inventors have surprisingly found that compositions comprising selected ingredients, namely thymol and terpineol, in selective proportions provide relatively quick antimicrobial action. | 2011-09-15 |
20110223115 | SUBLINGUAL BUCCAL EFFERVESCENT - A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed. | 2011-09-15 |
20110223116 | APPARATUS AND METHOD FOR AEROSOL DELIVERY TO THE LUNGS OR OTHER LOCATIONS OF THE BODY - This disclosure relates to an apparatus useful for the delivery of aerosols, such as those containing drugs, to the lungs or other locations in the body. The disclosure also relates to methods of administering an aerosol to the lungs or other locations in the body of a patient. | 2011-09-15 |
20110223117 | ALPHA-GLUCANASE AND ORAL CARE COMPOSITION CONTAINING THE SAME - Isolated α-glucanases from | 2011-09-15 |
20110223118 | ANTIBACTERIAL PHARMACEUTICAL COMPOSITION COMPRISING ACERIPHYLLUM ROSSII EXTRACT AND ACTIVE COMPOUNDS ISOLATED THEREFROM - The present invention relates to an antibacterial pharmaceutical composition comprising an | 2011-09-15 |
20110223119 | METHOD FOR REMOVING SOLID PRODUCT FORMED ON SURFACES OF TEETH - The invention provides a composition capable of exerting an excellent whitening effect and imparting gloss to teeth. | 2011-09-15 |
20110223120 | Compositions Having a Plurality of Discrete Emulsions - A cosmetic composition comprising a first emulsion and a second emulsion and optionally one or more additional emulsions, each of said two or more emulsions being discretely contained within the composition and comprising an inner phase and an outer phase, each of said two or more emulsions being independently a water-in-oil emulsion, an oil-in-water emulsion, an oil-in-oil emulsion, a polyol-in-oil emulsion, a water-in-silicone emulsion, a silicone-in-water emulsion, or a polyol-in-silicone emulsion in physical contact with at least one other emulsion, at least one of said two or more emulsions being visually distinct from the others, and each of said two or more emulsions as well as said composition being independently both physically and visually stable within the composition for at least six months at ambient temperature. | 2011-09-15 |
20110223121 | DYESTUFFS OF PLANT ORIGIN AND USE THEREOF FOR COLOURING COMPOSITIONS, IN PARTICULAR COSMETIC COMPOSITIONS - Dyestuff of plant origin is obtained from a colored part of a plant species, the cell tissues of which contain iridisomes responsible for the coloration of said part. Most particularly, a blue dyestuff is obtained from the arils of the seeds of the plant species | 2011-09-15 |
20110223122 | SHINE-IMPARTING HYDRATING AND MOISTURIZING EMULSION LIPSTICK COMPOSITION - The present invention is directed to emulsion composition, in solid form, capable of imparting shine, hydration and/or moisturization onto lips containing: a) at least one polyamine; (b) at least one oil-soluble high carbon polar modified polymer; (c) water; (d) at least one non-volatile solvent; (e) at least one wax having a high melting point; and (e) optionally, at least one colorant. | 2011-09-15 |
20110223123 | WASHABLE WATERPROOF AND SMUDGE-RESISTANT MASCARA - The present invention is directed to a washable eye makeup composition having waterproof and smudge-resistant properties containing: (a) at least one oil-soluble high carbon polar modified polymer; (b) at least one polyamine; (c) water; (d) optionally, at least one non-volatile solvent capable of solubilizing the polar modified polymer; (d) at least one volatile solvent; and (e) at least one colorant. | 2011-09-15 |
20110223124 | HAIR CARE COMPOSITIONS AND METHODS - Described are hair care compositions, comprising transparent inorganic metal oxide sunscreen particles and at least one of a cosmetically acceptable surfactant, conditioning agent, styling agent, humectant, emollient, preservative, or rheology modifier. | 2011-09-15 |
20110223125 | COMPOSITIONS WITH FREEZE THAW STABILITY - Composition including freeze thaw stability polymer such as a copolymer having a weight average molecular weight of at least about 30,000 grams per mole, a blend of a first polymer and a second polymer, a crosslinked alkali swellable acrylate copolymer, or at least one polymerizable reactive alkoxylated acrylate monomer. The copolymer has one or more first monomeric units and one or more second monomeric units. The one or more first monomeric units each independently including at least one bicycloheptyl-polyether, bicycloheptenyl-polyether or branched (C | 2011-09-15 |
20110223126 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid. | 2011-09-15 |
20110223127 | SDF-1 Binding Nucleic Acids And The Use Thereof - The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells. | 2011-09-15 |
20110223128 | REGULATION OF MICROVASCULATURE OCCLUSION - The present invention provides compositions and methods to regulate embolic occlusion of the microvasculature. In particular, the present invention inhibits extravasation of emboli from microvasculature resulting in increased occlusion (e.g., by administering a MMP 2/9 inhibitor locally to a subject). | 2011-09-15 |
20110223129 | CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 2011-09-15 |
20110223130 | USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE - Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described. | 2011-09-15 |
20110223131 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2011-09-15 |
20110223132 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides compounds and salts of Formula I and Formula | 2011-09-15 |
20110223133 | THERAPEUTIC AGENT FOR HEMATOPOIETIC TUMORS - An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24. | 2011-09-15 |
20110223134 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): | 2011-09-15 |
20110223135 | SIMIAN ADENOVIRUSES SAdV-43, -45, -46, -47, -48, -49, AND -50 AND USES THEREOF - A recombinant vector comprises simian adenovirus 43, 45, 46, 47, 48, 49 or 50 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus 43, 45, 46, 47, 48, 49 or 50 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2011-09-15 |
20110223136 | NUTRITIONAL SUPPORT TO PREVENT AND/OR MITIGATE BONE MARROW TOXICITY FROM A CANCEROUS TUMOR - The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm. | 2011-09-15 |
20110223137 | COMPOSITIONS FOR USE IN LOW-BIRTH WEIGHT INFANTS - The present invention relates to compositions for use in low-birth weight infants. In particular, the compositions are probiotic compositions which are used for achieving full enteral feeding in low birth weight infants. The invention is also concerned with the use of specific probiotics in the manufacture of low-birth weight infant formulations. | 2011-09-15 |
20110223138 | Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins - The invention includes a purified population of mesenchymal stromal cells that have been cultured under conditions, such as having been contacted with an apoptotic cell, to express increased levels of at least one anti-apoptotic protein. Such mesenchymal stem cells may be used to treat diseases, disorders, or conditions associated with apoptosis or with unresolved inflammation. | 2011-09-15 |
20110223139 | RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND ORGAN TREATMENT AND REPAIR - A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition. | 2011-09-15 |
20110223140 | METHOD FOR DIFFERENTIATION INTO RETINAL CELLS FROM STEM CELLS - Disclosed is a method for inducing stem cells to differentiate into retinal cells at high yield within a short period of time, without gene implantation and co-culture with retinal tissues, by implementing a differentiation process similar to the in vivo embryonic development in chemically defined conditions. Also, retinal cells including the photoreceptor cells and their progenitor cells, and various types of other retinal cells, generated according to the method, are disclosed. A composition comprising the retinal cells and a method are provided for treating retinal degeneration-related diseases. The differentiated photoreceptor cells, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration. | 2011-09-15 |
20110223141 | TREATMENT OF BRAIN OR SPINAL CORD INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 2011-09-15 |
20110223142 | METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide. | 2011-09-15 |
20110223143 | STEM CELL FOR THERAPEUTIC USE WHICH IS DERIVED FROM HUMAN MONOCYTE, AND METHOD FOR INDUCING SAME - The present invention relates to stem cells obtained by culturing monocytes in the presence of (i) M-CSF and (ii) at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract, thereby dedifferentiating the monocytes; a therapeutic agent for treating damaged cells, tissues or organs; a cell drug agent; a method of producing stem cells, a culture medium for dedifferentiating monocytes; a dedifferentiation inducing agent; a cell drug kit; a kit for producing dedifferentiated cells; and a pharmaceutical composition. | 2011-09-15 |
20110223144 | Creation of a Biological Atrioventricular Bypass to Compensate for Atrioventricular Block - A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle. | 2011-09-15 |
20110223145 | IMMUNOSUPPRESSIVE BLOOD CELLS AND METHODS OF PRODUCING THE SAME - The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease. | 2011-09-15 |
20110223146 | METHODS FOR PREPARATION AND USE OF MARROW INFILTRATNG LYMPHOCTYES (MILS) - The invention provides compositions comprising activated marrow infiltrating lymphocytes, methods of generating populations of marrow infiltrating lymphocytes, uses of the marrow infiltrating lymphocytes of the invention, and a culture device for use in cell culture, for example for use in generating populations of activated marrow infiltrating lymphocytes. In certain embodiments, the marrow infiltrating lymphocytes can be used as a cancer therapeutic. | 2011-09-15 |
20110223147 | LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF - The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor. | 2011-09-15 |
20110223148 | THERAPEUTIC/PROPHYLACTIC AGENT FOR PROSTATE CANCER - Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided. | 2011-09-15 |
20110223149 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 2011-09-15 |
20110223150 | Neutraceutical-Based Topical Anxiolytic Agent and Method of Use - A nutraceutical-based anxiolytic agent (composition) for topical application is described. The formulation utilizes a combination of active ingredients directed to up-regulate the parasympathetic nervous system and calming vagal nerve enervation and its resultant stress symptomatology. The active ingredients in the topical composition include GABA (gamma-aminobutyric acid), L-theanine, Phenibut (beta-phenyl-gamma-aminobutyric acid), and casein tryptic hydrolysase. The active ingredients are dissolved in a lecithin organogel carrier such as Lipoderm or Phloderm to provide a superior transdermal delivery system. | 2011-09-15 |
20110223151 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY - The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia. | 2011-09-15 |
20110223152 | USE OF INHIBITORS OF LEUKOTRIENE B4 RECEPTOR BLT2 FOR TREATING HUMAN CANCERS - The present invention relates to a new use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers. More particularly, the present invention relates to a pharmaceutical composition for treating human cancers comprising BLT2 inhibitors and a method for treating human cancers using BLT2 inhibitors. | 2011-09-15 |
20110223153 | MODIFIED SILK FILMS CONTAINING GLYCEROL - The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be into 3-dimentional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels. | 2011-09-15 |
20110223154 | COMPOSITIONS INCLUDING TRICIRIBINE AND METHODS OF USE THEREOF - This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2011-09-15 |
20110223155 | ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 2011-09-15 |
20110223156 | REVERSIBLE GEL PROTEIN FORMULATION - Reversible gel protein formulations, including pharmaceutical formulations, that inhibit protein aggregate formation are described, along with containers, e.g., a vial, ampoule or bottle; or an apparatus or device, e.g., a syringe, comprising such formulations. Also described are methods for inhibiting protein aggregation in a protein-containing sample and methods for inhibiting particle formation in a protein-containing sample. | 2011-09-15 |
20110223157 | METHODS FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS USING LENALIDOMIDE, AND GENE AND PROTEIN BIOMARKERS AS A PREDICTOR - Methods of treating or managing specific cancers, including non-Hodgkin's lymphoma, by the administration of 3-(4-amino- | 2011-09-15 |
20110223158 | ASSOCIATION OF LEVELS OF HDL-CHOLESTEROL APOLIPOPROTEIN CIII WITH THE RISK OF CORONARY HEART DISEASE AND CARDIOVASCULAR EVENTS - Presented herein are methods of diagnosing, assessing, and treating an individual at increased risk if developing coronary heart disease or cardiovascular event, based on the individual's level of high density lipoprotein cholesterol apoCIII (HDL-C apoCIII). | 2011-09-15 |
20110223159 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 2011-09-15 |
20110223160 | COMPOSITIONS AND METHODS RELATING TO GLUCAGON RECEPTOR ANTIBODIES - The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment. | 2011-09-15 |
20110223161 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-15 |
20110223162 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB 1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-15 |
20110223163 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 2011-09-15 |
20110223164 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type lgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 2011-09-15 |
20110223165 | Humanized C-Kit Antibody - This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodies. | 2011-09-15 |
20110223166 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death - Compositions and methods for protecting neuronal cells from pressure-induced apoptotic cell death which comprises administering to a subject in need of such treatment at least one compound which directly or indirectly inhibits the activity of an ion channel on neuronal cells and thereby inhibits the effect of pressure on the cells. | 2011-09-15 |
20110223167 | COMBINATION THERAPY USING RECEPTOR TYROSINE KINASE INHIBITORS AND ANGIOGENESIS INHIBITORS - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of receptor tyrosine kinase antagonists/inhibitors, especially ErbB receptor antagonists, more preferably EGF receptor (Her 1) antagonists and anti-angiogenic agents, preferably integrin antagonists, optionally together with agents or therapy forms that have additive or synergistic efficacy when administered together with the combination of antagonists/inhibitors, such as chemotherapeutic agents and or radiation therapy. The therapy can result in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone. | 2011-09-15 |
20110223168 | LIGAND THAT HAS BINDING SPECIFICITY FOR IL-4 AND/OR IL-13 - The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity. | 2011-09-15 |
20110223169 | IL-17 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with an IL-17 antibody. | 2011-09-15 |
20110223170 | KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with a KLK-13 antibody. | 2011-09-15 |
20110223171 | Methods and Compositions for the Diagnosis and Treatment of Cyclin A-1 Associated Conditions - The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting cyclin A1. | 2011-09-15 |
20110223172 | Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof - This invention relates to soluble forms of F glycoprotein from Hendra and Nipah virus and to compositions comprising soluble forms of F glycoprotein from Hendra and Nipah virus. This invention further relates to soluble oligomers of F glycoprotein from Hendra and Nipah virus. This invention also relates to nucleic acids encoding soluble forms of F glycoprotein from Hendra and Nipah virus. This invention also relates to diagnostic and therapeutic methods using the soluble forms of F glycoprotein from Hendra and Nipah virus. Further, this invention relates to antibodies, including neutralizing antibodies, and to vaccines for the prevention, diagnosis and treatment of infection by Hendra and Nipah viruses. | 2011-09-15 |
20110223173 | Botulinum Neurotoxin A Receptor and the Use Thereof - The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism. | 2011-09-15 |
20110223174 | Nontypeable Haemophilus Influenzae Virulence Factors - The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of | 2011-09-15 |
20110223175 | Gene Encoding G-Protein Coupled Receptor And Gene Product Thereof - The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit. | 2011-09-15 |
20110223176 | BASIGIN BINDING PROTEINS - Isolated binding proteins, e.g., antibodies, which bind to Basigin (BSG), e.g., human BSG2, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 2011-09-15 |
20110223177 | TREATMENT OF FIBROTIC EYE DISORDERS - Inhibitors of myosin activity are used to treat or prevent a fibrotic disorder of the eye, for example posterior capsule opacification (PCO). | 2011-09-15 |
20110223178 | Antibodies That Specifically Bind to Chemokine Beta-4 - The present invention relates to antibodies and related molecules that specifically bind to CK-β4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-β4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to CK-β4. | 2011-09-15 |
20110223179 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition. | 2011-09-15 |
20110223180 | METHODS AND COMPOSITIONS RELATED TO A MULTI-METHYLATION ASSAY TO PREDICT PATIENT OUTCOME - Methods and compositions for the prognosis and classification of cancer, especially brain tumor, are provided. For example, in certain aspects methods for cancer prognosis using methylation analysis of selected biomarkers are described. | 2011-09-15 |
20110223181 | Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium - Provided herein are methods for treating ovarian serous papillary carcinoma by delivering | 2011-09-15 |
20110223182 | MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung. | 2011-09-15 |
20110223183 | HUMAN NOTCH3 BASED FUSION PROTEINS AS DECOY INHIBITORS OF NOTCH3 SIGNALING - This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder. | 2011-09-15 |
20110223184 | DKK2 PROTEIN AND USE THEREOF - The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same. | 2011-09-15 |
20110223185 | CHIMERIC HEPATITIS C VIRUS ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HVC core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response. | 2011-09-15 |
20110223186 | Clostridium toxin, and process for the preparation of immunogenic composition - The present invention relates to the field of bacterial toxic proteins, in particular toxins from | 2011-09-15 |
20110223187 | LIVE LISTERIA-BASED VACCINES FOR CENTRAL NERVOUS SYSTEM THERAPY - This invention is directed to methods for treating a central nervous system (CNS) tumor or cancer using live | 2011-09-15 |
20110223188 | TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER - Compositions are provided that are targeted to tumors or tumor-associated neovasculature and enhance the function of tumor-infiltrating T cells. The compositions include fusion proteins that contain a T cell binding domain and a tumor/tumor-associated neovasculature targeting domain. The fusion proteins optionally contain a peptide/polypeptide linker domain and a domain that mediates dimerization or multimerization. The T cell binding domain can be a costimulatory molecule. Methods for using the fusion proteins to enhance an immune response are provided. Therapeutic uses for the disclosed compositions include the induction of tumor immunity. | 2011-09-15 |
20110223189 | AGENT FOR TREATING LEISHMANIA INFECTIONS - The invention relates to using a combination of DNA-expression constructs for producing a drug for immunisation against | 2011-09-15 |
20110223190 | Methods for the administration of FV and related compositions - The present invention is generally directed to methods for the administration of compositions related to improved physical performance and post-exertion recovery, as well as the administered compositions. It is more specifically directed to compositions containing a FV extract and methods for using such compositions that, among other things, improve lactic acid clearance, muscle reaction time, stamina, exertion recovery time and reduce fatigue. In an extract aspect, the | 2011-09-15 |
20110223191 | ANTI-CANCER NUTRACEUTICAL COMPOSITION - A comestible composition with anti-cancer property comprises alcohol soluble extracts from plant parts of | 2011-09-15 |
20110223192 | METHODS FOR DELAYING THE ONSET AND/OR REDUCING THE SEVERITY OF METABOLIC SYNDROME - The present invention provides dietary supplements, medical foods, and methods effective to delay the onset, slow the progression, and/or ameliorate at least one of the symptoms of a metabolic disease or disorder, such as metabolic syndrome, type I diabetes, type II diabetes, pancreatic disease, and/or hyperlipidemia. | 2011-09-15 |
20110223193 | METHOD FOR THE PREPARATION OF MEDICAL DEVICES AND DEVICES OBTAINED THEREFROM - Method of selecting and preparing medical devices comprising extracts of plants and natural substances devoid of pharmacologically, immunologically or metabolically active fractions and characterised by a content of substances able to exert beneficial effects on the body, mediated by mechanical or physical effects, which said process comprises:
| 2011-09-15 |
20110223194 | VACCINE - A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen. | 2011-09-15 |
20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS - The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues. | 2011-09-15 |
20110223196 | HIV/SIV VACCINES FOR THE GENERATION OF MUCOSAL AND SYSTEMIC IMMUNITY - Compositions of genetically engineered, secreted gp96 (gp69-Ig) induced strong mucosal and systemic immune responses and CD8 expansion that was independent of CD4 help. Immunization of patients with gp96-Ig immunization is especially attractive for induction of mucosal and systemic immunity to SIV/HIV and other diseases. | 2011-09-15 |
20110223197 | Mucosal and Systemic Immunization with Alphavirus Replicon Particles - Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described. | 2011-09-15 |
20110223199 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 2011-09-15 |
20110223200 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis | 2011-09-15 |
20110223201 | Immunonanotherapeutics Providing a Th1-Biased Response - Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable. | 2011-09-15 |
20110223202 | CATIONIC CORE-SHELL PEPTIDE NONOPARTICLES - The invention discloses an amphiphilic antimicrobial substance comprising a hydrophobic portion coupled to a cationic oligopeptide portion. The cationic oligopeptide portion may comprise a protein transduction domain coupled to a cationic oligopeptide group. | 2011-09-15 |
20110223203 | NANOCLUSTER COMPOSITIONS AND METHODS - Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm. | 2011-09-15 |
20110223204 | TREATMENT OF PAIN WITH GAP JUNCTION MODULATION COMPOUNDS - The present invention relates to delivery, including transdermal delivery, of a therapeutically effective amount of a compound useful for modulating gap junction formation and function, including an oligonucleotide for reducing gap junction formation and function, and methods and compositions for treating a subject suffering from pain associated with a disease, disorder or condition and associated with pain, including but not limited to muscle pain, ligament pain, tendon pain, joint pain and post-operative pain. | 2011-09-15 |
20110223205 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING UMBILICAL DERIVED CELLS - This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient. | 2011-09-15 |
20110223206 | MICELLE COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a micelle composition comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymeric unit X and the hydrophilic block B comprises at least one hydrophilic polymeric unit Y whereby the X and Y blocks alternate. | 2011-09-15 |
20110223207 | Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided. | 2011-09-15 |
20110223208 | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations - The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations and methods of making and using them. | 2011-09-15 |